Skip to main content

Table 6 Bleeding and coagulation.

From: Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study

 

HES 130/0.4(n = 100)

NaCl 0.9%(n = 96)

P value

Number of patients with RBC transfusions, n (%)

29 (29.0)

20 (20.8)

0.2480

Volume (ml) of RBC transfusions, n (mean ± SD, range)

100 (214 ± 358, 0 to 1,394)

96 (165 ± 354, 0 to 1,661)

0.3415

Blood loss, ml, including blood sampling and drainage, n (mean ± SD, range)

63 (10.0 ± 24.4, 0.4 to 150.7)

65 (10.5 ± 29.4, 0.2 to 207.8)

NS

Coagulation parameters, median values over time

INR

aPTT (ratio)

INR

aPTT (ratio)

P value

Baseline

1.3

1.2

1.3

1.2

 

Until HDSa

0.1

0.2

0.0

0.1

 

Day 1

0.0

0.1

0.0

0.1

 

Day 2

-0.1

0.1

-0.1

0.0

 

Day 3

-0.1

0.1

-0.2

0.0

 

Day 4

-0.2

0.1

-0.2

-0.1

 

Day 5

-0.1

0.0

-0.1

-0.1

 

Day 8b

-0.1

0.0

-0.2

0.0

 

Lastc

-0.1

0.0

-0.2

0.0

 
  1. aFirst measurement until HDS visit (i.e., data recorded at day of withdrawal were assigned to the study visit corresponding to the actual time point of measurement); bdata recorded on Day 8; clast available post-baseline measurement; RBC, red blood cell; SD, standard deviation; HDS, hemodynamic stabilization; HES, hydroxyethyl starch; NaCI, sodium chloride.